BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ChamberMaster//Event Calendar 2.0//EN
METHOD:PUBLISH
X-PUBLISHED-TTL:P1H
REFRESH-INTERVAL:P1H
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
DTSTART:20070101T000000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:Eastern Daylight Time
END:DAYLIGHT
BEGIN:STANDARD
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
DTSTART:20070101T000000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:Eastern Standard Time
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261106T110000
DTEND;TZID=America/New_York:20261106T120000
X-MICROSOFT-CDO-ALLDAYEVENT:FALSE
SUMMARY:Methodological Quality and Scientific Validity Under the MDR Description: Methodological Quality and Scientific Validity Under the MDR
DESCRIPTION:Under the MDR\, clinical evaluation must include an appraisal of clinical data to determine whether the evidence is suitable for establishing a device's safety and performance. If the data are insufficient\, CE marking can be delayed or put at risk. \nMethodological quality and scientific validity are central to that appraisal. Manufacturers need to understand how their clinical data will be evaluated\, what makes evidence suitable for its intended purpose\, and how those conclusions should be documented in the Clinical Evaluation Report (CER). MEDDEV 2.7/1 Rev 4 provides detailed guidance on clinical data appraisal. MDCG 2020-13 sets out how notified bodies should document their clinical evaluation assessments. The challenge for manufacturers is ensuring that their study data will meet MDR expectations and withstand notified body assessment.\n\nOn November 6\, Maria E. Donawa\, M.D.\, joins Friday In Focus to explain how clinical data appraisal works under the MDR and what manufacturers should consider when designing studies to support CE marking.
X-ALT-DESC;FMTTYPE=text/html:Under the MDR\, clinical evaluation must include an appraisal of clinical data to determine whether the evidence is suitable for establishing a device's safety and performance. If the data are insufficient\, CE marking can be delayed or put at risk. \nMethodological quality and scientific validity are central to that appraisal. Manufacturers need to understand how their clinical data will be evaluated\, what makes evidence suitable for its intended purpose\, and how those conclusions should be documented in the Clinical Evaluation Report (CER). MEDDEV 2.7/1 Rev 4 provides detailed guidance on clinical data appraisal. MDCG 2020-13 sets out how notified bodies should document their clinical evaluation assessments. The challenge for manufacturers is ensuring that their study data will meet MDR expectations and withstand notified body assessment.\n\nOn November 6\, Maria E. Donawa\, M.D.\, joins Friday In Focus to explain how clinical data appraisal works under the MDR and what manufacturers should consider when designing studies to support CE marking.
LOCATION:
UID:e.1244.1686682
SEQUENCE:3
DTSTAMP:20261112T170404Z
URL:https://massmedic.growthzoneapp.com/events/Details/methodological-quality-and-scientific-validity-under-the-mdr-description-methodological-quality-and-scientific-validity-under-the-mdr-1989048?sourceTypeId=Hub
END:VEVENT
END:VCALENDAR